Introduction Melanoma is an aggressive skin cancer and accounts for the majority of skin cancer deaths, according to the American Cancer Society ( www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/ ). The melanoma incidence rate is increasing worldwide, and the disease is among the top 10…
Introduction Metastatic brain tumors (MBT) arise from cancers outside the central nervous system (CNS). They reach the brain either from hematogenous spread or via direct invasion from adjacent tissues. Brain metastases are the most common brain tumors and occur nearly…
Introduction Metastatic melanoma in the brain is a serious event in patients with melanoma because it signifies a poor prognosis and has a potentially severe impact on quality of life. In 20% of cases, symptomatic metastases represent the initial site…
Introduction Melanoma is the fastest growing malignancy in the United States in terms of incidence. In the year 2015, it is estimated that 73,870 men and women will be diagnosed with cutaneous melanoma in the United States and that 9940…
Introduction Epidemiology Brain metastases are estimated to be the most common intracranial malignancy in adults ( ). However, the exact incidence is unknown as epidemiological, clinical, neurosurgical, and autopsy series present different incidence rates due to different patient selections. Autopsy…
Introduction Brain metastases are a serious consequence of many solid tumors, which can result in significant morbidity and mortality. Approximately 10–20% of cancer patients develop brain metastases, and while the actual incidence of brain metastases is somewhat difficult to quantify,…
Research highlights Treatment options for myeloma bone disease have increased during the last years. Denosumab is an RANKL inhibitor that has shown its noninferiority in SRE prevention compared to zoledronic acid. Denosumab may constitute a safer option for patients with…
Research highlights Myeloma growth leads to an imbalance of osteoclasts and osteoblasts causing osteolytic bone disease. Multiple cell types within the bone marrow influence myeloma cell colonization, survival, and growth or dormancy. Repairing existing bone lesions remains a current challenge…
Research highlights Bone is the preferred site of metastasis in breast cancer, especially in ER/PR-positive tumors CDK4/6 inhibitors combined with aromatase inhibitors/fulvestrant prolong PFS including in patients with bone metastases In HER2-positive patients with bone metastases new combined therapies and…
Intended figures 1. PSMA PET/CT-illustrating scan of both skeletal and local recurrence 2. “Dual-alpha technology” Introduction When treating patients with primary bone cancers and bone metastatic disease, clinicians need to consider best combinations of the various treatments available. Optimal management…